Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe Sells 142,886 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 142,886 shares of the company’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $29.93, for a total transaction of $4,276,577.98. Following the sale, the chief financial officer now directly owns 112,186 shares of the company’s stock, valued at approximately $3,357,726.98. This represents a 56.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, October 14th, Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.31, for a total transaction of $5,478,399.09.
• On Monday, October 7th, Oluyemi Okupe sold 9,868 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.96, for a total transaction of $196,965.28.
• On Friday, September 20th, Oluyemi Okupe sold 12,651 shares of Hims & Hers Health stock. The stock was sold at an average price of $16.79, for a total transaction of $212,410.29.
• On Tuesday, September 3rd, Oluyemi Okupe sold 11,609 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.60, for a total transaction of $169,491.40.

Hims & Hers Health Price Performance

HIMS stock traded down $0.60 during midday trading on Friday, reaching $20.25. 6,051,112 shares of the company were exchanged, compared to its average volume of 9,139,706. The business has a 50-day moving average price of $19.64 and a two-hundred day moving average price of $18.78. Hims & Hers Health, Inc. has a one year low of $7.40 and a one year high of $30.44. The firm has a market capitalization of $4.35 billion, a price-to-earnings ratio of 47.38 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company’s revenue for the quarter was up 77.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.04) earnings per share. As a group, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors have recently modified their holdings of HIMS. Nisa Investment Advisors LLC lifted its position in Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares during the period. Quest Partners LLC raised its stake in Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after acquiring an additional 3,507 shares in the last quarter. CWM LLC increased its stake in shares of Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after buying an additional 1,054 shares during the period. Van ECK Associates Corp acquired a new position in shares of Hims & Hers Health in the second quarter valued at approximately $111,000. Finally, Amalgamated Bank increased its stake in shares of Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after buying an additional 2,354 shares during the period. Institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on HIMS. TD Cowen increased their price target on shares of Hims & Hers Health from $25.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 8th. Canaccord Genuity Group increased their target price on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price for the company. Truist Financial increased their price objective on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, July 18th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Hims & Hers Health presently has an average rating of “Hold” and a consensus price target of $21.21.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.